**Acute phase**

**Intermediate phase**

**Chronic phase**

Period of overlap to achieve effective bridging therapy

Possible options

VKA

Initial treatment with UFH, LMWH or fondaparinux

VKA

Switch to a NOAC

Potential single-drug approach using a NOAC

**Longer than 3 months**

**Up to 3 months**

**Up to 5 days**

Time